Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting
Fig 1
Sensitivity vs specificity at ≥20 days.
Sensitivity against specificity for the kits tested (IgG only, and positive or negative result for the LumiraDx assay). For each kit the ≥20 days post symptom onset sensitivity is shown. The MHRA targets of 98% sensitivity and specificity and additional 95% sensitivity cut off are shown as dotted lines. Pharmact was not included on the graph due to low specificity. The devices that did not progress beyond this stage are shown in red.